Abstracts Archive - Page 1654 of 2607 - ACR Meeting Abstracts

Abstract Number: 818 • 2016 ACR/ARHP Annual Meeting
The Role of Endothelin 1 in Activation of Vascular Smooth Muscle Cells in Systemic Sclerosis; Increased Cell Proliferation and Resistance to Apoptosis Mediated By Endotehlin B Receptors
Shadia Nada¹, Yongqing Wang^1,2, Nezam Altorok¹ and Bashar Kahaleh¹, ¹Medicine/Rheumatology, University of Toledo, Toledo, OH, ²Medicine, University of Toledo, Toledo, OH
Background/Purpose: is overexpressed in SSc as illustrated by elevated circulating levels and increased tissue expression in involved organs. We previously reported vascular smooth muscle…
Abstract Number: 819 • 2016 ACR/ARHP Annual Meeting
Impaired Adiponectin Signaling in SSc Contributes to Myofibroblast Differentiation and Organ Fibrosis
Roberta Goncalves Marangoni¹, Benjamin Korman², Feng Fang¹, Monique Hinchcliff¹, Laszlo Otvos³, Philipp E. Scherer⁴, Warren Tourtellotte⁵ and John Varga⁶, ¹Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ²Department of Rheumatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL, ³Temple University, Philadelphia, PA, ⁴University of Texas Southwestern Medical Center, Dallas, TX, ⁵Department of Pathology, Ward, Northwestern University, Chicago, IL, ⁶Rheumatology and Dermatology, Northwestern University, Feinberg School of Medicine Scleroderma Program, Chicago, IL
Background/Purpose: In systemic sclerosis (SSc) patients, skin fibrosis is accompanied by involution of dermal white adipose tissue (dWAT), a prominent source of adiponectin (APN). We…
Abstract Number: 820 • 2016 ACR/ARHP Annual Meeting
EZH2 Modulates Angiogenesis and Fibrosis in Scleroderma
Pei-Suen Tsou, Patrick Coit, Dinesh Khanna and Amr H Sawalha, Division of Rheumatology, University of Michigan, Ann Arbor, MI
Background/Purpose: Scleroderma (SSc) is a complex disease that involves activation of the immune system, vascular complications, and tissue fibrosis. Although the pathogenesis of this disease…
Abstract Number: 821 • 2016 ACR/ARHP Annual Meeting
IL-31 Is an Inflammatory Pro-Fibrotic Factor Elevated in a Subset of Scleroderma Patients with Severe Pruritus
Bahja Ahmed Abdi¹, Sara Zafar², Zeinab Taki³, Nikita Arumalla⁴, Shiwen Xu⁵, Christopher Denton⁴, David Abraham⁴ and Richard J. Stratton⁶, ¹Division of Medicine, Centre for Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ²Centre of Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ³Department of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ⁴Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ⁵Division of Medicine, Centre for Rheumatology and Connective tissue disease, University College London, London, United Kingdom, ⁶Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom
Background/Purpose: Systemic sclerosis (SSc) is an autoimmune rheumatic disease associated with fibroblast activation in the skin and visceral organs. In SSc, refractory pruritus is a…
Abstract Number: 822 • 2016 ACR/ARHP Annual Meeting
Pulmonary Fibrosis in Mixed Connective Tissue Disease – Results from an Unselected Longitudinal Cohort
Silje Reiseter¹, Trond Mogens Aalokken², Ragnar Gunnarsson³, May Brit Lund⁴, Johanna Haydon⁵ and Øyvind Molberg^6,7, ¹Rheumatology, University of Oslo, Rikshospitalet, Oslo, Norway, ²Radiology, Oslo University Hospital, Oslo, Norway, ³Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, ⁴Respiratory Medicine, Oslo University Hospital, Oslo, Norway, ⁵Rheumatology, Vestre Viken Hospital, Drammen, Norway, ⁶Institute of Clinical Medicine, University of Oslo, Oslo, Norway, ⁷Rheumatology, Oslo University Hospital, Oslo, Norway
Background/Purpose: Mixed Connective Tissue Disease (MCTD) is a chronic, immune-mediated disorder defined by the combined presence of serum anti-ribonucleoprotein (RNP) antibodies and selected clinical features…
Abstract Number: 823 • 2016 ACR/ARHP Annual Meeting
A Phase 2 Study of Pomalidomide (CC-4047) to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Effectiveness in Subjects with Systemic Sclerosis with Interstitial Lung Disease
Vivien Hsu¹, Christopher P.Denton², Robyn T. Domsic³, Daniel E. Furst⁴, Maureen Rischmueller⁵, Marina Stanislav⁶, Virginia D. Steen⁷, Douglas Hough⁸, Shimon Korish⁹, Alyse Cooper¹⁰, Peter H. Schafer¹¹ and Suktae Choi¹², ¹Rheumatology, RWJ Med Schl Scleroderma Prog, New Brunswick, NJ, ²Centre of Rheumatology and Connective Tissue Diseases, University College London, London, United Kingdom, ³Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, ⁴David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁵University of Adelaide, Adelaide, Australia, ⁶Research Rheumatology Institute n. a. V.A. Nassonova, Moscow, Russia, ⁷Rheumatology, Georgetown University Medical Center, Washington, DC, ⁸Clinical Research, Celgene Corporation, Warren, NJ, ⁹33 Technology Drive, Celgene Corporation, Warren, NJ, ¹⁰Immunology & Inflammation, Clinical Research, Celgene Corporation, Summit, NJ, ¹¹Department of Translational Development, Celgene Corporation, Summit, NJ, ¹²Biostatistics, Celgene Corporation, Summit, NJ
Background/Purpose: Pomalidomide (POM) is an IMiD compound, structurally similar to thalidomide. POM binds to cereblon and facilitates Ikaros and Aiolos degradation, resulting in immunomodulation of…
Abstract Number: 824 • 2016 ACR/ARHP Annual Meeting
Mycophenolate Versus Placebo for the Treatment of Systemic Sclerosis-Related Interstitial Lung Disease
Elizabeth R. Volkmann¹, Donald P. Tashkin², Ning Li³, Michael Roth⁴, Dinesh Khanna⁵, Anna-Maria Hoffmann-Vold⁶, Philip J. Clements⁴, Daniel E. Furst¹, Robert Elashoff⁷ and Scleroderma Lung Study II Group, ¹University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ²David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, CA, ³UCLA, Los Angeles, CA, ⁴Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁵University of Michigan, Ann Arbor, MI, ⁶Oslo University Hospital, Oslo, Norway, ⁷Biomathematics, University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Compared with placebo, treatment with cyclophosphamide (CYC) improved lung function and dyspnea in patients with systemic sclerosis-related interstitial lung disease (SSc-ILD).1 While treatment with…
Abstract Number: 825 • 2016 ACR/ARHP Annual Meeting
KL-6 and Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis Related Interstitial Lung Disease
Gloria Salazar¹, Masataka Kuwana², Minghua Wu¹, Jun Ying¹, Julio Charles³, Maureen D Mayes¹ and Shervin Assassi¹, ¹Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, ²Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ³Internal Medicine-Rheumatology, University of Texas-McGovern Medical School, Houston, TX
Background/Purpose: Pneumoproteins are attractive biomarker candidates in systemic sclerosis (SSc) related interstitial lung disease (ILD) because they are easily obtainable and lung-specific. KL-6 and CCL-18…
Abstract Number: 826 • 2016 ACR/ARHP Annual Meeting
Exercise Echocardiography Predicts Future Development of Pulmonary Hypertension in a High-Risk Cohort of Scleroderma Patients
Kaitlin A. Quinn¹, Tunay Kuru², Stephanie Wappel³ and Virginia D. Steen¹, ¹Rheumatology, Georgetown University Medical Center, Washington, DC, ²Pulmonary, Georgetown University Medical Center, Washington, DC, ³Georgetown University Medical Center, Washington, DC
Background/Purpose: Pulmonary hypertension (PH) is the leading cause of scleroderma related deaths and is often detected late in the disease course. Early identification of patients…
Abstract Number: 827 • 2016 ACR/ARHP Annual Meeting
Severe Gastrointestinal Disease in Early Systemic Sclerosis Is Associated with an Increased Risk of Mortality
Nicolas Richard¹, Marie Hudson², Mianbo Wang³, Murray Baron⁴, Genevieve Gyger¹ and Canadian Scleroderma Research Group, ¹McGill University, Jewish General Hospital, Montreal, QC, Canada, ²Medicine/Rheumatology, Jewish General Hospital, Lady Davis Research Institute, Montreal, QC, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Studies of severe gastrointestinal (GI) disease in systemic sclerosis (SSc) are limited by small, selected samples composed largely of subjects with prevalent disease. We…
Abstract Number: 828 • 2016 ACR/ARHP Annual Meeting
Survival and Health-Related Quality of Life in Incident Systemic Sclerosis Related Pulmonary Arterial Hypertension: A Multicentre Australian Cohort Study
Kathleen Morrisroe¹, Molla Huq², Wendy Stevens³, Candice Rabusa⁴, Joanne Sahhar⁵, Gene Ngian⁶, Susanna Proudman^7,8, Mandana Nikpour⁹ and Australian Scleroderma Interest Group, ¹Rheumatology, St Vincent's Hospital, Melbourne, Melbourne, Australia, ²Department of Medicine (Rheumatology), Melbourne University, Melbourne, Australia, ³Department of Rheumatology, St. Vincent’s Hospital Melbourne, Melbourne, Australia, ⁴Rheumatology, St. Vincent’s Hospital, Melbourne, Australia, ⁵Department of Rheumatology, Monash Medical Centre, Melbourne, Australia, ⁶Department of Medicine (RMH/WH), The University of Melbourne, Melbourne, Australia, ⁷Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ⁸Discipline of Medicine, University of Adelaide, Adelaide, Australia, ⁹Melbourne University, Melbourne, Australia
Background/Purpose: Pulmonary arterial hypertension (PAH) is the leading cause of systemic sclerosis (SSc) related mortality. We sought to determine survival, predictors of mortality, and health…
Abstract Number: 829 • 2016 ACR/ARHP Annual Meeting
High Level of Chemokine CCL2 Is Associated with Lung Fibrosis Progression and Reduced Survival in Two Independent Systemic Sclerosis Cohorts
Anna Hoffmann-Vold¹, Richard Huyen², Elizabeth R. Volkmann², Oyvind Midtvedt¹, Vyacheslav Palchevskiy², May Brit Lund³, Torhild Garen¹, Trond Mogens Aalokken⁴, Anders Heiervang Tennøe¹, Stephen Samuel Weigt², Mike Shino², Rajan Saggar⁵, David Ross², Joseph Lynch III², Thor Ueland⁶, Michael Fishbein⁷, Pål Aukrust⁸, Øyvind Molberg¹ and John A Belperio², ¹Rheumatology, Oslo University Hospital, Oslo, Norway, ²University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³Respiratory Medicine, Oslo University Hospital, Oslo, Norway, ⁴Radiology, Oslo University Hospital, Oslo, Norway, ⁵Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ⁶Research, Oslo University Hospital, Oslo, Norway, ⁷Pathology and Laboratory Medicine, University of California, Los Angeles, Los Angeles, CA, ⁸Research Intitute for Internal Medicine, Oslo University Hospital, Rikshospitalet, Oslo, Norway
Background/Purpose: Markers for early identification of progressive interstitial lung disease (ILD) in systemic sclerosis (SSc) are in demand. The proto-typical inflammatory chemokine CCL2 has been linked…
Abstract Number: 830 • 2016 ACR/ARHP Annual Meeting
Cardiopulmonary Disease Development in Anti-RNA Polymerase III Positive Systemic Sclerosis; Comparative Analyses from an Unselected, Prospective Patient Cohort
Anna Hoffmann-Vold¹, Anders Heiervang Tennøe², Oyvind Midtvedt², May Brit Lund³, Torhild Garen², Fadi El-Hage⁴, Trond Mogens Aalokken⁵, Eli Taraldsrud⁴ and Øyvind Molberg², ¹Division of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Rheumatology, Oslo University Hospital, Oslo, Norway, ³Respiratory Medicine, Oslo University Hospital, Oslo, Norway, ⁴Oslo University Hospital, Oslo, Norway, ⁵Radiology, Oslo University Hospital, Oslo, Norway
Background/Purpose: Extensive skin disease and renal crisis are hallmarks of anti-RNA polymerase III (RNAP) positive systemic sclerosis (SSc), while data on lung and heart involvement…
Abstract Number: 831 • 2016 ACR/ARHP Annual Meeting
Immunosuppression May Prevent Interstitial Lung Disease in Systemic Sclerosis
Sabrina Hoa¹, Marie Hudson², Mianbo Wang³, Russell Steele⁴, Murray Baron⁵ and Canadian Scleroderma Research Group, ¹Division of Rheumatology, Jewish General Hospital, Lady Davis Institute, Montreal, QC, Canada, ²Jewish General Hospital, Lady Davis Institute and McGill University, Montreal, QC, Canada, ³Lady Davis Institute for Medical Research, Montreal, QC, Canada, ⁴Mathematics, McGill University, Montreal, QC, Canada, ⁵Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of premature mortality in systemic sclerosis (SSc). Immunosuppression is used for treatment of established disease. However,…
Abstract Number: 832 • 2016 ACR/ARHP Annual Meeting
Defining Skin Ulcers in Systemic Sclerosis: A Systematic Literature Review of Skin Ulcer Definitions and a Preliminary Consensus-Based New SSc Skin Ulcer Definition
Yossra A Suliman¹, Cosimo Bruni², Sindhu R. Johnson³, Emanuela Praino⁴, Mohamed Alemam⁵, Nabeel Borazan⁶, Laura Cometi⁷, Bethany Myers⁸, Dinesh Khanna⁹, Yannick Allanore¹⁰, Murray Baron¹¹, Thomas Krieg¹², Ariane L. Herrick¹³, Suzanne Kafaja¹⁴, Christopher Denton¹⁵, Marco Matucci Cerinic¹⁶ and Daniel E. Furst¹⁷, ¹Rheumatology and Rehabilitation dept., Rheumatology and Rehabilitation dept. Assiut university hospital, Assiut Egypt, Assiut, Egypt, ²Department of Biomedicine, Division of Rheumatology AOUC, Excellence Centre for Research, Florence, Italy, ³Rheumatology, Mount Sinai Hospital and University Health Network, Toronto, ON, Canada, ⁴DIM, Rheumatology Unit, Bari, Italy, ⁵Clinical Pathology and Laboratory Medicine Department, Assistant Lecturer, Qena, Egypt, ⁶Medicine, David Geffen School of Medicine, Los Angeles, CA, ⁷Division of Rheumatology, Department of Experimental and Clinical Medicine,, Florencei, Italy, ⁸UCLA Louise M. Darling Biomedical Library, Research Informationist, Los Angeles, CA, ⁹University of Michigan, Ann Arbor, MI, ¹⁰Immunogenetics, Cochin Institute, Paris, France, ¹¹Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, ¹²Universität zu Köln, Köln, Germany, ¹³Centre for Musculoskeletal Research, University of Manchester, MAHSC, Salford Royal Hospital, Manchester, United Kingdom, ¹⁴Medicine/Rheumatology, University of California Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ¹⁵Division of Medicine, Centre for Rheumatology and Connective Tissue Disease, University College London, London, United Kingdom, ¹⁶Department of BioMedicine, Division of Rheumatology, Transition Unit, University of Florence, Firenze, Italy, ¹⁷University of California, Los Angeles, Los Angeles, CA
Background/Purpose: Skin ulcers in SSc are a major clinical challenge and there are various un-validated definitions of skin ulcers utilized in SSc-related clinical trials. We…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].